Overall, the small sample is a major limitation due to oritavancin formulary availability and AMA event documentation (became a discrete EMR field in 2014) preventing OAB group expansion. ...lack of standardized scoring tools to objectively categorize SSTI severity prevents consistent assessment and makes comparisons with oritavancin and standard therapy difficult. Additional studies in high-acuity settings with larger sample sizes are needed to identify the optimal population for oritavancin.Funding This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.Credit authorship contribution statement John Paul A. Sacdal: Writing – review & editing, Writing – original draft, Investigation, Formal analysis, Data curation.